DelveInsight Business Research LLP

DelveInsight’s ‘Fuchs Endothelial Corneal Dystrophy – Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the Fuchs Endothelial Corneal Dystrophy, historical and forecasted epidemiology as well as the Fuchs Endothelial Corneal Dystrophy market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

Key Highlights of the Fuchs Endothelial Corneal Dystrophy  Market 

• The Key Companies working in the Fuchs Endothelial Corneal Dystrophy market include Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon, Emmecell, and many others.

• The Key Therapies working in the Fuchs Endothelial Corneal Dystrophy market include TTHX1114(NM141), Netarsudil, Ripasudil, Amphotericin B, and many others.

Fuchs Endothelial Corneal Dystrophy  Overview

Fuchs Endothelial Corneal Dystrophy is a non-inflammatory, sporadic, or autosomal-dominant dystrophy involving the endothelial layer of the cornea. Fuchs’ dystrophy swells the cornea, causing glare, halo, and reduced visual acuity. The damage to the cornea in Fuchs’ endothelial dystrophy can be severe, causing corneal blindness. Fuchs Endothelial Corneal Dystrophy is characterized by an asymmetrical, bilateral, slowly progressive edema of the cornea in elderly patients. When inherited, the transmission is autosomal dominant. The corneal endothelium is a monolayer of cells that acts as the major pump for the deturgescence of the cornea and ensures clarity. The normal attrition rate of endothelial cells is 0.6% per year; the rate is accelerated in Fuchs Endothelial Corneal Dystrophy.The root cause of the condition is a slowly progressive form of guttate lesions between the corneal endothelium and the Descemet membrane. These wartlike, anvil-shaped, or mushroom-shaped excrescences are abnormal elaborations of basement membrane and fibrillar collagen by distressed or dystrophic endothelial cells. As the lesions enlarge, the covering endothelial cells become stretched, eventually falling off.

Fuchs Endothelial Corneal Dystrophy Epidemiology Insights

• According to DelveInsight estimates, in 2021, the total diagnosed prevalent cases of Fuchs Endothelial Corneal Dystrophy were estimated to be approximately 18,813,111 in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.6% during the study period (2019–2032).

• Among the 7MM, the United States accounted for nearly 34% of the total diagnosed prevalent cases of Fuchs Endothelial Corneal Dystrophy in the 7MM in the year 2021, which is expected to increase further by 2032.

• As per DelveInsight analysis, in EU4 and the United Kingdom, Germany had the highest total diagnosed prevalent cases of Fuchs Endothelial Corneal Dystrophy with approximately 2,448,548 in 2021, while Spain had the lowest diagnosed prevalent population of Fuchs Endothelial Corneal Dystrophy with 1,390,771 cases in 2021.

Click here to learn more about the Fuchs Endothelial Corneal Dystrophy Market Landscape

The Report Covers the Fuchs Endothelial Corneal Dystrophy   Epidemiology Segmented by:

• Fuchs Endothelial Corneal Dystrophy  diagnosed cases 

• Fuchs Endothelial Corneal Dystrophy  incident cases

• Fuchs Endothelial Corneal Dystrophy  prevalent cases 

• Fuchs Endothelial Corneal Dystrophy  treatment cases 

Fuchs Endothelial Corneal Dystrophy Market Outlook 

Medical management of early Fuchs Endothelial Corneal Dystrophy is limited to decreasing corneal edema with topical sodium chloride 5% drops, hypertonic saline drops, and solutions (ophtasyloxane) or ointments to shorten the morning edema and facilitate corneal dehydration.

Phototherapeutic keratectomy, amniotic membrane transplants, anterior stromal puncture, and conjunctival flaps are also used to relieve painful symptoms, especially those associated with ruptured bullae in the later stages of the disease. Even cycloplegic, antibiotic ointment and patching are prescribed to treat ruptured corneal bullae. If a persistent or large epithelial defect is there, then bandage contact lenses are recommended.

However, these treatments do not have any curative effect because they do not act on the cause of the disease, which is the dysfunction of the endothelial layer. Frequency of usage has no effect; it only provides temporary relief and does not change the course of the disease; also, there is a stinging associated with these agents, which reduces acceptance.

Key Companies Working in the Fuchs Endothelial Corneal Dystrophy Market

• Kowa Pharmaceuticals

• Trefoil Therapeutics

• Alcon

• Emmecell

And many others.

Fuchs Endothelial Corneal Dystrophy Therapies Covered and Analyzed in the Report

• TTHX1114(NM141)

• Netarsudil

• Ripasudil

• Amphotericin B

And many others 

Learn more about the Key Companies and Emerging Therapies in the Fuchs Endothelial Corneal Dystrophy Market

Table of Contents 

1. Key Insights 

2. Fuchs Endothelial Corneal Dystrophy Introduction 

3. Executive Summary of Fuchs Endothelial Corneal Dystrophy             

4. Disease Background and Overview

5. Epidemiology and Patient Population

6. Fuchs Endothelial Corneal Dystrophy Emerging Therapies

7. Fuchs Endothelial Corneal Dystrophy Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Fuchs Endothelial Corneal Dystrophy  Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services